<?xml version='1.0' encoding='utf-8'?>
<document id="29645280"><sentence text="Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy."><entity charOffset="10-21" id="DDI-PubMed.29645280.s1.e0" text="Vemurafenib" /><entity charOffset="66-73" id="DDI-PubMed.29645280.s1.e1" text="Digoxin" /><pair ddi="false" e1="DDI-PubMed.29645280.s1.e0" e2="DDI-PubMed.29645280.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29645280.s1.e0" e2="DDI-PubMed.29645280.s1.e1" /></sentence><sentence text="The primary objective of this phase 1, open-label, multicenter, 3-period, fixed-sequence study was to evaluate the effect of multiple doses of vemurafenib on the pharmacokinetics of a single dose of digoxin, a probe P-glycoprotein (P-gp) substrate, in patients with BRAFV600 mutation-positive metastatic malignancy"><entity charOffset="143-154" id="DDI-PubMed.29645280.s2.e0" text="vemurafenib" /><entity charOffset="199-206" id="DDI-PubMed.29645280.s2.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.29645280.s2.e0" e2="DDI-PubMed.29645280.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29645280.s2.e0" e2="DDI-PubMed.29645280.s2.e1" /></sentence><sentence text=" Following a 28-day screening period, patients received a single oral dose of digoxin 0"><entity charOffset="78-85" id="DDI-PubMed.29645280.s3.e0" text="digoxin" /></sentence><sentence text="25 mg on day 1 in period A, oral vemurafenib 960 mg twice daily for 21 days in period B (days 8-28), and a single oral dose of digoxin 0"><entity charOffset="33-44" id="DDI-PubMed.29645280.s4.e0" text="vemurafenib" /><entity charOffset="127-134" id="DDI-PubMed.29645280.s4.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.29645280.s4.e0" e2="DDI-PubMed.29645280.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29645280.s4.e0" e2="DDI-PubMed.29645280.s4.e1" /></sentence><sentence text="25 mg on day 29 and vemurafenib 960 mg twice a day for 7 days (days 29-35) in period C"><entity charOffset="20-31" id="DDI-PubMed.29645280.s5.e0" text="vemurafenib" /></sentence><sentence text=" Log-transformed area under the concentration-time curve and peak concentration values for digoxin were compared between periods A (digoxin alone) and C (digoxin + vemurafenib) using an analysis of variance model"><entity charOffset="91-98" id="DDI-PubMed.29645280.s6.e0" text="digoxin" /><entity charOffset="151-152" id="DDI-PubMed.29645280.s6.e1" text="C" /><entity charOffset="154-175" id="DDI-PubMed.29645280.s6.e2" text="digoxin + vemurafenib" /><pair ddi="false" e1="DDI-PubMed.29645280.s6.e0" e2="DDI-PubMed.29645280.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29645280.s6.e0" e2="DDI-PubMed.29645280.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29645280.s6.e0" e2="DDI-PubMed.29645280.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29645280.s6.e1" e2="DDI-PubMed.29645280.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29645280.s6.e1" e2="DDI-PubMed.29645280.s6.e2" /></sentence><sentence text=" Twenty-six patients were evaluated for the primary pharmacokinetic analysis" /><sentence text=" The geometric mean ratio (period C/period A) of area under the curve to the last measurable concentration for digoxin was 1"><entity charOffset="111-118" id="DDI-PubMed.29645280.s8.e0" text="digoxin" /><entity charOffset="34-40" id="DDI-PubMed.29645280.s8.e1" text="C" /><pair ddi="false" e1="DDI-PubMed.29645280.s8.e1" e2="DDI-PubMed.29645280.s8.e1" /><pair ddi="false" e1="DDI-PubMed.29645280.s8.e1" e2="DDI-PubMed.29645280.s8.e0" /></sentence><sentence text="82 (90%CI 1"><entity charOffset="7-7" id="DDI-PubMed.29645280.s9.e0" text="C" /></sentence><sentence text="63 to 2" /><sentence text="02), and the geometric mean ratio of peak concentrations was 1" /><sentence text="47 (90%CI 1"><entity charOffset="7-7" id="DDI-PubMed.29645280.s12.e0" text="C" /></sentence><sentence text="30 to 1" /><sentence text="65); the 90%CIs were outside of the equivalence limits of 0"><entity charOffset="12-12" id="DDI-PubMed.29645280.s14.e0" text="C" /></sentence><sentence text="82 to 1" /><sentence text="22, indicating an effect of vemurafenib on digoxin"><entity charOffset="28-39" id="DDI-PubMed.29645280.s16.e0" text="vemurafenib" /><entity charOffset="43-50" id="DDI-PubMed.29645280.s16.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.29645280.s16.e0" e2="DDI-PubMed.29645280.s16.e0" /><pair ddi="false" e1="DDI-PubMed.29645280.s16.e0" e2="DDI-PubMed.29645280.s16.e1" /></sentence><sentence text=" Multiple oral doses of vemurafenib were generally well tolerated, with an adverse event profile similar to that previously seen in phase 2 and 3 studies of vemurafenib monotherapy"><entity charOffset="24-35" id="DDI-PubMed.29645280.s17.e0" text="vemurafenib" /><entity charOffset="157-168" id="DDI-PubMed.29645280.s17.e1" text="vemurafenib" /><pair ddi="false" e1="DDI-PubMed.29645280.s17.e0" e2="DDI-PubMed.29645280.s17.e0" /><pair ddi="true" e1="DDI-PubMed.29645280.s17.e0" e2="DDI-PubMed.29645280.s17.e1" /></sentence><sentence text=" This study confirmed vemurafenib as an inhibitor of P-gp in vivo with a statistically significant drug-drug interaction with digoxin"><entity charOffset="22-33" id="DDI-PubMed.29645280.s18.e0" text="vemurafenib" /><entity charOffset="126-133" id="DDI-PubMed.29645280.s18.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.29645280.s18.e0" e2="DDI-PubMed.29645280.s18.e0" /><pair ddi="false" e1="DDI-PubMed.29645280.s18.e0" e2="DDI-PubMed.29645280.s18.e1" /></sentence><sentence text=" Caution should be exercised when dosing vemurafenib concurrently with P-gp substrates"><entity charOffset="41-52" id="DDI-PubMed.29645280.s19.e0" text="vemurafenib" /><entity charOffset="1-11" id="DDI-PubMed.29645280.s19.e1" text="C" /><pair ddi="false" e1="DDI-PubMed.29645280.s19.e1" e2="DDI-PubMed.29645280.s19.e1" /><pair ddi="false" e1="DDI-PubMed.29645280.s19.e1" e2="DDI-PubMed.29645280.s19.e0" /></sentence><sentence text="" /></document>